CN Patent

CN112218634A — 具有驱动致癌突变的癌症的治疗

Assigned to G1 Therapeutics Inc · Expires 2021-01-12 · 5y expired

What this patent protects

描述了通过组合施用CDK4/6抑制剂与另外的激酶抑制剂来治疗具有特定致癌驱动突变的癌症的方法和组合物，其中该特定组合提供有利的或协同的抑制活性，延迟对其他激酶抑制剂的获得性抗性，和/或扩展激酶抑制剂的功效。

USPTO Abstract

描述了通过组合施用CDK4/6抑制剂与另外的激酶抑制剂来治疗具有特定致癌驱动突变的癌症的方法和组合物，其中该特定组合提供有利的或协同的抑制活性，延迟对其他激酶抑制剂的获得性抗性，和/或扩展激酶抑制剂的功效。

Drugs covered by this patent

Patent Metadata

Patent number
CN112218634A
Jurisdiction
CN
Classification
—
Expires
2021-01-12
Drug substance claim
No
Drug product claim
No
Assignee
G1 Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.